anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: People with epilepsy desire to acquire accurate information about epilepsy and actively engage in its management throughout the long journey of living with seizures. ChatGPT is a large language model and we aimed to assess the accuracy and consistency of ChatGPT in responding to the common concerns of people with epilepsy and to evaluate its ability to provide emotional support.
METHODS: Questions were collected from the International League against Epilepsy and the China Association against Epilepsy. The responses were independently assessed by two board-certified epileptologists from the China Association against Epilepsy, and a third reviewer resolved disagreements. The reviewers assessed its ability to provide emotional support subjectively.
RESULTS: A total of 378 questions related to epilepsy and 5 questions related to emotional support were included. ChatGPT provided "correct and comprehensive" answers to 68.4% of the questions. The model provided reproducible answers for 82.3% questions. The model performed poorly in answering prognostic questions, with only 46.8% of the answers rated as comprehensive. When faced with questions requiring emotional support, the model can generate natural and understandable responses.
SIGNIFICANCE: ChatGPT provides accurate and reliable answers to patients with epilepsy and is a valuable source of information. It also provides partial emotional support, potentially assisting those experiencing emotional distress. However, ChatGPT may provide incorrect responses, leading users to inadvertently accept incorrect and potentially dangerous advice. Therefore, the direct use of ChatGPT for medical guidance is not recommended and its primary use at present is in patients education.
Kinesio® Tex GoldFP (USA) was applied on both feet in the prone position with the knee extended, and the feet in a slightly plantar flexed position and hanging off the bed. The first Kinesio-taping was cut as an I shape and prepared for the transverse arch ligament correction technique. The non-stretched starting anchor was attached to the dorsum of the 5th metatars on the lateral side of the foot, passed from the plantar surface to the medial side with 75-100% tension. The non-stretched end was attached to the medial side of the ankle over the navicular region. The non-stretched initial anchor of the second Kinesio-taping strip starting from the proximal dorsal of the 5th. metatarsal on the lateral side of the foot.
The research study will compare Pennsaid to placebo. The placebo looks like Pennsaid, but it doesn't contain any Pennsaid. The investigators use placebos in research to see if the results are due to the study drug or to other reasons. At some time during the study the investigators will give the patient Pennsaid. At another time, the investigators will give the patient placebo. The investigators are using Quantitative Sensory Testing (QST), which is temperature testing before and after using the study drug to see if Pennsaid is helpful in reducing people's nerve pain.

In this test, a small metal plate, about the size of a matchbox, is put on the area where the patient has pain. The plate is connected to a computer that can warm or cool the plate. The patient will use a computer mouse button to tell us when the plate feels warm. The QST machine is approved by the Food and Drug Administration (FDA). It is often used by nerve doctors to see if a person has neuropathy (pain caused by damage to a nerve).
Subarachnnoid hemorrhage (SAH) present in a spectrum of clinical severity, from alert with a headache to comatose. High-grade SAH has higher mortality and risk for severe complications including acute respiratory distress syndrome (ARDS) and delayed cerebral ischemia (DCI). Existing treatment approaches for ARDS in SAH require special consideration because of potential impact on intracranial pressure and cerebral perfusion. DCI is a major cause of SAH morbidity and is often discordant with angiographic vasospasm. Current treatment approaches for DCI and vasospasm require further investigation to determine efficacy and risk/benefit. Nimodipine remains the only therapeutic that is proven to improve SAH outcome.
The invention relates to gemcitabine amino acid injection, and belongs to the technical field of pharmaceutical preparations. Gemcitabine amino acid injection, which comprises the following components: gemcitabine and acidic amino acids. The acidic amino acid is glutamic acid or aspartic acid; glutamic acid is preferred. The solubility of the gemcitabine glutamic acid injection prepared by the invention can reach 20-40mg/ml, and the solubility is good by preparing an acidic amino acid solution in the solution. The gemcitabine glutamic acid injection prepared by the invention has pH4-5, good physical and chemical stability, no vascular irritation to patients and no pain and irritation inflammation on the upper arm of the injected medicament. The water soluble preparation has convenient use, less pollution, simple preparation process and low cost.
FIELD: medicinal biotechnology, immunology. SUBSTANCE: invention relates to method for preparing monoclonal antibody (monAT) and its fragment using hybridome FERM BR-4382 that produces the above-mentioned antibody. For hybridome preparing the recombinant granulocyte colony-stimulating factor rG-CSF is used. The produced monAT belongs to class IgG. Fragment monAT represents F(ab) 2 - fragment. MonAT is able to recognize antigen causing apoptosis of bone marrow myeloid cells and shows also property to induce apoptosis of myeloma cells that ensures to use its as effective medicinal agent for usage in the case of myelocytic leucosis. EFFECT: valuable properties of antibody. 7 cl, 21 dwg
Obesity is a chronic disease caused by the accumulation of excessive adipose tissue. This disorder is characterized by chronic low‑grade inflammation, which promotes the release of proinflammatory mediators, including cytokines, chemokines and leptin. Simultaneously, chronic inflammation can predispose to cancer development, progression and metastasis. Proinflammatory molecules are involved in the recruitment of specific cell populations in the tumor microenvironment. These cell populations include myeloid‑derived suppressor cells (MDSCs), a heterogeneous, immature myeloid population with immunosuppressive abilities. Obesity‑associated MDSCs have been linked with tumor dissemination, progression and poor clinical outcomes. A comprehensive literature review was conducted to assess the impact of obesity‑associated MDSCs on cancer in both preclinical models and oncological patients with obesity. A secondary objective was to examine the key role that leptin, the most important proinflammatory mediator released by adipocytes, plays in MDSC‑driven immunosuppression Finally, an overview is provided of the different therapeutic approaches available to target MDSCs in the context of obesity‑related cancer.
FIELD: medicine, obstetrics, prophylaxis. SUBSTANCE: it is suggested to prescribe a food additive named "Bumivit-C" at the dosage of 15-20 g daily since the 21st-23d wk of gestation period. The method enables to increase efficiency in preventing pyelonephritis by 95.65%, decrease the frequency of complications occurring in the course of pregnancy. It is characterized by the absence of negative impact upon a fetus along with strengthening the maternal organism. EFFECT: higher efficiency of prophylaxis. 3 ex, 1 tbl
We anticipate that caregivers will be interested in participating in the intervention, be open to randomization, and have good rates of compliance with the program. It is also expected that MBSR program participants will evidence a trend toward better outcomes than CESS participants on primary outcome measures of perceived stress, psychological distress and perceived caregiver burden.

Substudy The purpose of this proposal is to add a physiologic outcome sub-study to the Balance project that will examine four biological markers correlated with stress in caregivers participating in the study intervention. The Balance Study is a recently funded NIH randomized controlled pilot study to evaluate the acceptability and feasibility of a Mindfulness-Based Stress Reduction (MBSR) intervention for caregivers of patients with dementia. Balance is randomizing caregivers (N=60) into equal numbers to participate in either an intervention arm consisting of a MBSR program that includes eight weeks of group instruction in mindfulness meditation techniques followed by home practice or an active control arm consisting of a standard eight week community Caregiver Education and Social Support (CESS) program. The specific aims of this study are to: 1) evaluate the feasibility of adding physiologic markers to the Balance Study; 2) examine changes over time in individual study participants on four biological markers correlated with stress including interleukin 6 (IL-6), D-dimer, DHEA-S and telomere length; and 3) to examine preliminary differences between MBSR and CESS groups on four biological markers. The addition of physiologic outcomes to the Balance Study presents an emerging opportunity to increase the competitiveness for our NIH R01 application.
In pooled analyses of patients, voriconazole was shown to be effective against the following additional fungal pathogens:

Scedosporium apiospermum \- Successful response to voriconazole therapy was seen in 15 of 24 patients (63%). Three of these patients relapsed within 4 weeks, including 1 patient with pulmonary, skin and eye infections, 1 patient with cerebral disease, and 1 patient with skin infection. Ten patients had evidence of cerebral disease and 6 of these had a successful outcome (1 relapse). In addition, a successful response was seen in 1 of 3 patients with mixed organism infections. 

Fusarium spp. - Nine of 21 (43%) patients were successfully treated with voriconazole. Of these 9 patients, 3 had eye infections, 1 had an eye and blood infection, 1 had a skin infection, 1 had a blood infection alone, 2 had sinus infections, and 1 had disseminated infection (pulmonary, skin, hepatosplenic). Three of these patients (1 with disseminated disease, 1 with an eye infection and 1 with a blood infection) had Fusarium solani and were complete successes. Two of these patients relapsed, 1 with a sinus infection and profound neutropenia and 1 post surgical patient with blood and eye infections.
Mirtazapine tablets, USP contain mirtazapine, USP. Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro-2-methylpyrazino [2,1-a] pyrido [2,3-c][2] benzazepine and has the empirical formula of C17H19N3. Its molecular weight is 265.35. The structural formula is the following and it is the racemic mixture:

Mirtazapine is a white to creamy white crystalline powder which is practically insoluble in water.

Mirtazapine tablets are available for oral administration as scored film-coated tablets containing 15 mg or 30 mg of mirtazapine, and unscored film-coated tablets containing 7.5 mg or 45 mg of mirtazapine.

Each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, and titanium dioxide. The 7.5 mg tablets also contain sunset yellow FCF lake and Allura red AC lake. The 15 mg tablets also contain iron oxide yellow, quinoline yellow lake and sunset yellow FCF lake. The 30 mg tablets also contain ferric oxide yellow, ferric oxide red and ferrosoferric oxide/iron oxide black.

FDA approved dissolution method differs from the USP dissolution testing.
Negation scope analysis for negation detection is provided. In various embodiments, a phrase is read from a report collection. The phrase is searched for at least one of a predetermined set of negation keywords. A dependency parse tree is generated of the phrase. The dependency parse tree is traversed starting with the at least one of the predetermined set of negation keywords. Based on the traversal, a plurality of words of the phrase are determined that are spanned by the at least one of the predetermined set of negation keywords.
The present disclosure relates to hair-treatment compositions, which are particularly useful for providing styling, hair manageability, hair care, and conditioning properties to hair. The hair-treatment compositions typically include: (a) about 1 to about 3 wt. % of one or more vegetable oils; (b) about 2 to about 4 wt. % of one or more solid fatty alcohols; (c) 1 wt. % or less of one or more nonionic surfactants; (d) one or more non-silicone shine enhancers; (e) one or more amidoamines: (f) one or more acids; and (g) water. The unique combination of ingredients results in a product having a milky appearance and a fluid viscosity. Kits comprising the hair-treatment compositions and methods of treating hair using the hair-treatment compositions are also disclosed.
The invention relates to a pharmaceutical composition for treating diabetes, and belongs to the technical field of medicines. The pharmaceutical composition is prepared from the following medicines in parts by weight: 30-70 parts of 60%-70% polysaccharide, 25-60 parts of 70%-85% saponin and 5-10 parts of 55%-70% flavones. Common fenugreek seeds are adopted as a main raw material; and the astragalus membranaceus is taken as an auxiliary material. The invention provides a method for effectively separating and purifying the polysaccharide, the saponin and the flavones in the common fenugreek seeds and the astragalus membranaceus. Through intensive study and combination of the polysaccharide, the saponin and the flavones, the effective component content is high; the toxicity and the side effect of the medicine are removed; the quality is easy to control; the blood glucose of diabetic animals can be significantly reduced; and the pharmaceutical composition has good prevention and treatment effects on diabetes and complications. The diabetes is treated by combined components of the traditional Chinese medicines; the preparation technology is easy to industrialize; the pharmaceutical composition has great and profound meaning for modernization of the traditional Chinese medicine and marching for the international market.
The invention relates to a traditional Chinese medicine preparation for treating gynecologic diseases, such as pelvic cavity blood stasis diseases, vaginitis, pelvic inflammation, cervicitis, irregular menstruation and the like. The traditional Chinese medicine preparation is characterized by comprising the following raw materials by weight: 30-40g of gingko nut, 10-20g of caulis clematidis armandii, 40-50g of plantain seed, 10-20g of sargentgloryvine stem, 20-30g of oriental wormwood, 30-35g of dahurian patrinia, 65-75g of fossilia ossis mastodi, 10-20g of oyster, 10-20g of phellodendron and 20-30g of yam. The preparation method comprises the following steps: mixing the raw material medicines together, grinding into a powder shape and preparing traditional Chinese medicine medicinal powder. By the clinical tests of many years, the invention forms the traditional Chinese medicine preparation for treating the gynecologic diseases by researching the function and indication of each kind of medicine according to modern traditional Chinese medicine pharmacodynamics and carries out the clinical tests of analyzing, differentiating, applying and treating of traditional Chinese medicine subtypes on nearly more than one thousand cases of gynecologic common diseases. The invention has short treatment course, high curative effect, low treating expense and no adverse reaction and side effect. The clinical treatment proves that the cure rate reaches 92.5%, the medicine effect is obvious, and the curative effect is very satisfactory to people.
The invention relates to a traditional Chinese medicine used for treating headache and dizziness. The traditional Chinese medicine is prepared from Chinese medicine raw materials of, by weight: 450 to 550 parts of licorice, 25 to 30 parts of asurum uropeum, 40 to 60 parts of Taiwan angelica root, 8 to 10 parts of borneol, and 15 to 20 parts of menthol. The preparation method of the medicine is simple. The medicine can be prepared into traditional Chinese medicine powders and solutions. The traditional Chinese medicine is easy to take, and provides good and fast curative effects. With the traditional Chinese medicine, headache and dizziness are not easy to reoccur.
To obtain the sample size, the proportion of patients presenting adverse reactions that require interrupting chemotherapy treatment will be taken into account. In the institution, this figure is close to 15%. Since it is a dietary supplement, with extensive information on the safety of the product, the design is used in a stage of Flemming (without early stop rules). Assuming that the Ocoxin-Viusid product would clearly be declared ineffective (maximal ineffectiveness) if the proportion of patients not presenting adverse reactions was equal to less than 85% (p0), that is the maximum level of success below which the product does not shows signs of efficacy (the study does not guarantee further research) and taking a p1 value of 95%, where p1 is the minimum level of efficacy required from which the product would be declared effective (the results guarantee to continue a study phase III). Assuming an α error of 5% (probability of rejecting the null hypothesis when it is true) and β (probability of rejecting the alternative hypothesis when it is true) of 20% (the power of the test: 1 - β = 80%), It is determined to recruit a maximum number of 59 - 60 subjects. Determine a = 54, where a is the number of responses equal and below which the product is declared ineffective (H0 is accepted). And r = a + 1 is the cut-off point, that is, the number of responses from which the efficacy level ensures to continue to a phase III study. In this case we would expect to obtain a number of successes ≥ 55.

Patients will be randomized after surgery, in the chemotherapy consultation, and once they meet the established inclusion criteria. In order to achieve the masking of the research product, these have been labeled by a balanced randomized list obtained by computer, which will be in the possession of the Biostatistician of the study of the Clinical Investigations Section of INOR and the promoter. The product under study has been consecutively labeled from 1 to 120 (60 patients in each therapeutic arm).
During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
BACKGROUND: Successful deployment of clinical prediction models for clinical deterioration relates not only to predictive performance but to integration into the decision making process. Models may demonstrate good discrimination and calibration, but fail to match the needs of practising acute care clinicians who receive, interpret, and act upon model outputs or alerts. We sought to understand how prediction models for clinical deterioration, also known as early warning scores (EWS), influence the decision-making of clinicians who regularly use them and elicit their perspectives on model design to guide future deterioration model development and implementation.
METHODS: Nurses and doctors who regularly receive or respond to EWS alerts in two digital metropolitan hospitals were interviewed for up to one hour between February 2022 and March 2023 using semi-structured formats. We grouped interview data into sub-themes and then into general themes using reflexive thematic analysis. Themes were then mapped to a model of clinical decision making using deductive framework mapping to develop a set of practical recommendations for future deterioration model development and deployment.
RESULTS: Fifteen nurses (n = 8) and doctors (n = 7) were interviewed for a mean duration of 42 min. Participants emphasised the importance of using predictive tools for supporting rather than supplanting critical thinking, avoiding over-protocolising care, incorporating important contextual information and focusing on how clinicians generate, test, and select diagnostic hypotheses when managing deteriorating patients. These themes were incorporated into a conceptual model which informed recommendations that clinical deterioration prediction models demonstrate transparency and interactivity, generate outputs tailored to the tasks and responsibilities of end-users, avoid priming clinicians with potential diagnoses before patients were physically assessed, and support the process of deciding upon subsequent management.
CONCLUSIONS: Prediction models for deteriorating inpatients may be more impactful if they are designed in accordance with the decision-making processes of acute care clinicians. Models should produce actionable outputs that assist with, rather than supplant, critical thinking.
This open label multicenter study will evaluate the safety and efficacy of I.V. Oncocort Dexamethasone sodium phosphate given as a short term induction therapy in Multiple Myeloma patients. It consist of a Phase 1 part with a maximum number of 5 ascending dose levels while additional patients will be treated in the Phase 2a part with the recommended phase 2 dose to obtain additional safety data and preliminary efficacy data in multiple myeloma patients. For the dose escalation phase 1 part, 3 patients per dose level will be enrolled. If one patient reaches DLT, another 3 patients will be enrolled in the same dose level. If two or more patients reach DLT in one dose level, maximum tolerated dose (MTD) is defined at the last dose level beneath DLT. Not more than 5 dose level groups are anticipated for this part of the study. MTD will be the Recommended Phase II Dose (RPTD) for the phase IIa part of the study. For the phase 2a part, 7 additional patients will be enrolled at the RPTD dose level, bringing the total number of patients monitored for responses at this dose level to at least 10.
SLC26A4 encodes pendrin, a crucial anion exchanger essential for maintaining hearing function. Mutations in SLC26A4, including the prevalent c.919-2 A > G splice-site mutation among East Asian individuals, can disrupt inner ear electrolyte balance, leading to syndromic and non-syndromic hearing loss, such as Pendred syndrome and DFNB4. To explore potential therapeutic strategies, we utilized CRISPR/Cas9-mediated exon skipping to create a Slc26a4∆E8+E9/∆E8+E9 mouse model. We assessed pendrin expression in the inner ear and evaluated vestibular and auditory functions. The Slc26a4∆E8+E9/∆E8+E9 mice demonstrated reframed pendrin in the inner ear and normal vestibular functions, contrasting with severely abnormal vestibular functions observed in the Slc26a4 c.919-2 A > G splicing mutation mouse model. However, despite these molecular achievements, hearing function did not show the expected improvement, consistent with observed pathology, including cochlear hair cell loss and elevated hearing thresholds. Consequently, our findings highlight the necessity for alternative genetic editing strategies to address hearing loss caused by the SLC26A4 c.919-2 A > G mutation.